Specific criteria for diagnosing drug-induced lupus have not been formally established. However, symptoms often overlap with those of systemic lupus erythematosus (SLE). These include: muscle and ...

Current treatment options for systemic lupus erythematosus (SLE ... is being treated for a disease flare or shortly thereafter. Drugs most commonly used in this setting are antimalarials and ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...

BACKGROUND: Statins have been increasingly associated with drug-induced autoimmune reactions, including lupus erythematosus. OBJECTIVE: To identify and determine the clinical and biological ...

Which antiarrhythmic drug can cause drug induced lupus erythematosus? Procainamide can cause drug induced systemic lupus erythematosus (SLE). Anti-histone antibodies are present in about 95% of cases.

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus medication litifilimab. In return, Royalty Pharma will receive undisclosed ...

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing ...

Significantly, chronic exposure to procainamide may cause drug-induced lupus erythematosus. Disopyramide may be used for vagally mediated AF and obstructive hypertrophic cardiomyopathy.

Specific criteria for diagnosing drug-induced lupus have not been formally established. However, symptoms often overlap with those of systemic lupus erythematosus (SLE). These include: muscle and ...

Systemic lupus erythematosus (SLE ... The heterogeneous and flaring nature of the disease makes assessment of drug efficacy in clinical trials difficult, and a lack of clarity from regulatory ...